Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer.
CytomX Therapeutics, Inc,this week Pfizer Inc. notified the Bay Area-based company of its intent to terminate its five-year-old oncology collaboration.